(Reuters) - GlaxoSmithKline has asked a federal judicial panel to consolidate a dozen lawsuits alleging that its anti-nausea medication Zofran can cause birth defects in children born to women who took the drug while pregnant.
In a filing with the U.S. Judicial Panel on Multidistrict Litigation on Monday, the drugmaker said the cases should be transferred to federal court in Pennsylvania, where its U.S.-based operations are headquartered.
To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/1Co2miN
Our Standards: The Thomson Reuters Trust Principles.